| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:3 | Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits | Nervous system disease | WPHA/WNT Endorsed | Human, Rat | 0.14 | KE:188 | Neuroinflammation |
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.25 | KE:149 | Increase, Inflammation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:28 | Cyclooxygenase inhibition leading reproductive failure | Reproductive system disease | - | 0.17 | KE:49 | Reduction, Ca and HCO3 transport to shell gland | |
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal system disease | WPHA/WNT Endorsed | Human, Rat | 0.43 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:55 | Increase, Cell injury/death | ||||||
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.4 | KE:272 | Activation/Proliferation, T-cells |
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Human, Mouse, Rat | 0.06 | KE:457 | Activation, SREBF1 |
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.25 | KE:386 | Decrease of neuronal network function |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.25 | KE:386 | Decrease of neuronal network function |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.5 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| KE:767 | Increase, Hyperplasia (renal tubular cells) | ||||||
| KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | ||||||
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.4 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
| KE:716 | Increase, cell proliferation (hepatocytes) | ||||||
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.33 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| KE:777 | Increase, Inflammation (corneal cells) | ||||||
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.4 | KE:149 | Increase, Inflammation |
| KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | ||||||
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.2 | KE:800 | Decreased, Aromatase (Cyp19a1) mRNA |
| KE:799 | Increased, HIF-1 heterodimer | ||||||
| AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited metabolic disorder | WPHA/WNT Endorsed | Mouse, Rat, Human, Japanese quail, Chicken, Herring gull, Common Starling | 0.17 | KE:850 | Induction, CYP1A2/CYP1A5 |
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.22 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:425 | Decrease of Thyroidal iodide | ||||||
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.14 | KE:870 | Increase, Cell Proliferation | |
| AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal system disease | Under Review | Human, Mouse, Rat | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:1494 | Leukocyte recruitment/activation | ||||||
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.2 | KE:933 | KE6 : Depletion, Nitric Oxide |
| KE:937 | KE7 : Impaired, Vasodilation | ||||||
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.29 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.25 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.4 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:425 | Decrease of Thyroidal iodide | ||||||
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.4 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:425 | Decrease of Thyroidal iodide | ||||||
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1154 | Increased, Triiodothyronine (T3) in tissues |
| KE:1829 | Altered, Thyroid hormone-dependent gene expression | ||||||
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | Homo sapiens | 0.17 | KE:149 | Increase, Inflammation |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.5 | KE:1280 | Activation, HIF-1 |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1281 | Increased, DNA Damage-Repair | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.17 | KE:1390 | Sexual behavior, decreased |
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.4 | KE:1392 | Oxidative Stress |
| KE:1393 | Hepatocytotoxicity | ||||||
| AOP:228 | NSAID induced PTGS2 inactivation to gastric ulcer | Gastrointestinal system disease | - | 0.2 | KE:1411 | Increased, leukocyte activation | |
| AOP:237 | Substance interaction with lung resident cell membrane components leading to atherosclerosis | Cardiovascular system disease | Under Development | Human, Mouse | 0.2 | KE:1496 | Increased, secretion of proinflammatory mediators |
| AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | Lemna minor, Lemna gibba | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:256 | Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.2 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| AOP:257 | Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse, Dog, Monkey | 0.2 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.4 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular system disease | Under Development | Vertebrates | 0.12 | KE:1536 | Disruption, Intracellular calcium mobilization |
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.29 | KE:870 | Increase, Cell Proliferation |
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.25 | KE:55 | Increase, Cell injury/death | |
| KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal system disease; Respiratory system disease | - | 0.14 | KE:149 | Increase, Inflammation | |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.25 | KE:1821 | Decrease, Cell proliferation |
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.25 | KE:1821 | Decrease, Cell proliferation |
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.44 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:1494 | Leukocyte recruitment/activation | ||||||
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.44 | KE:1493 | Increased Pro-inflammatory mediators | |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:1494 | Leukocyte recruitment/activation | ||||||
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.43 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:320 | Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality | Unclassified | Under Development | Homo sapiens | 0.11 | KE:1496 | Increased, secretion of proinflammatory mediators |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.09 | KE:592 | Reduced, survival | |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | - | 0.11 | KE:1793 | Activator protein 1 activation | |
| AOP:348 | Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory | Unclassified | Under Development | Fish | 0.2 | KE:406 | decreased, Fertility |
| AOP:349 | Inhibition of 11β-hydroxylase leading to decresed population trajectory | Unclassified | Under Development | Fish | 0.12 | KE:406 | decreased, Fertility |
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased | |
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased | |
| AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous system disease | Under Development | Human | 0.5 | KE:188 | Neuroinflammation |
| KE:352 | N/A, Neurodegeneration | ||||||
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.5 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.12 | KE:1821 | Decrease, Cell proliferation |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.5 | KE:1497 | Increased, recruitment of inflammatory cells | |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.67 | KE:1607 | Increase, Necrosis |
| KE:759 | Increased, Kidney Failure | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1445 | Increase, Lipid peroxidation | ||||||
| AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:1920 | Altered gene expression, TGF-β dependent fibrosis pathway | |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.18 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:436 | Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries | Cardiovascular system disease | - | Chicken, Mouse, Vertebrates | 0.2 | KE:1881 | Decreased, all-trans retinoic acid (atRA) concentration |
| AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary system disease | Under Development | 0.4 | KE:1392 | Oxidative Stress | |
| KE:709 | Increase, Cytotoxicity (renal tubular cell) | ||||||
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.33 | KE:1971 | Increased, tumor growth |
| KE:149 | Increase, Inflammation | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.29 | KE:1974 | Activation of Tumor Protein 53 |
| KE:1262 | Apoptosis | ||||||
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.3 | KE:112 | Antagonism, Estrogen receptor |
| KE:1554 | Increase Chromosomal Aberrations | ||||||
| KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress | |
| AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural tube defect | - | 0.14 | KE:1502 | Histone deacetylase inhibition | |
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.44 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.18 | KE:1392 | Oxidative Stress | |
| KE:1262 | Apoptosis | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.33 | KE:1392 | Oxidative Stress |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:850 | Induction, CYP1A2/CYP1A5 | ||||||
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:2043 | Decrease, Sonic Hedgehog second messenger production | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous system disease | - | 0.11 | KE:1392 | Oxidative Stress | |
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular system disease | Under Review | Human, Rat, Mouse, Rabbit | 0.25 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1392 | Oxidative Stress | ||||||
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.3 | KE:1392 | Oxidative Stress |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular system disease; Thoracic disease | Under Development | 0.29 | KE:1392 | Oxidative Stress | |
| KE:55 | Increase, Cell injury/death | ||||||
| AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular system disease; Thoracic disease | Under Development | 0.2 | KE:40 | Decrease, Mitochondrial ATP production | |
| AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal system disease | Under Review | Human, Mouse, Rat, Rhesus monkeys | 0.14 | KE:1392 | Oxidative Stress |
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:2043 | Decrease, Sonic Hedgehog second messenger production | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:494 | AhR activation leading to liver fibrosis | Gastrointestinal system disease | - | Mus musculus, Homo sapiens | 0.17 | KE:55 | Increase, Cell injury/death |
| AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.1 | KE:1392 | Oxidative Stress |
| AOP:530 | Endocytotic lysosomal uptake leads to intestinal barrier disruption | Gastrointestinal system disease | - | 0.2 | KE:55 | Increase, Cell injury/death | |
| AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous system disease | - | Homo sapiens, Mus musculus | 0.17 | KE:149 | Increase, Inflammation |
| AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular system disease | - | 0.17 | KE:389 | Increased, Intracellular Calcium overload | |
| AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Rodents, Dog, Pig, Zebrafish | 0.17 | KE:389 | Increased, Intracellular Calcium overload |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:1262 | Apoptosis |
| AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | Zebrafish | 0.18 | KE:2301 | Abnormal, Behavior |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:2195 | Increase, CNS Neural cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.62 | KE:352 | N/A, Neurodegeneration |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:188 | Neuroinflammation | ||||||
| KE:52 | Decreased, Calcium influx | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.4 | KE:386 | Decrease of neuronal network function |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:52 | Decreased, Calcium influx | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.12 | KE:406 | decreased, Fertility |
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.4 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.08 | KE:345 | N/A, Liver Steatosis | |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.6 | KE:827 | sensitisation, skin |
| KE:272 | Activation/Proliferation, T-cells | ||||||
| KE:826 | Activation, Keratinocytes | ||||||
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.56 | KE:389 | Increased, Intracellular Calcium overload |
| KE:352 | N/A, Neurodegeneration | ||||||
| KE:55 | Increase, Cell injury/death | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:188 | Neuroinflammation | ||||||
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.4 | KE:386 | Decrease of neuronal network function |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:425 | Decrease of Thyroidal iodide | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | Medaka, Gammarus pulex, Hydra | 0.17 | KE:592 | Reduced, survival |
| AOP:95 | Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival | |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.29 | KE:636 | Decreased, survival |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.33 | KE:807 | Decreased, cholesterol |
| KE:330 | Decrease, Fertility | ||||||
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.25 | KE:885 | Increase, Cancer |
| AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.25 | KE:1250 | Decrease, Lung function |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.29 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory system disease | - | 0.22 | KE:1218 | Opening of calcium channel, Calcium influx | |
| KE:1226 | Increased Respiratory irritability and Chronic Cough, | ||||||
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.33 | KE:1263 | Necrosis |
| KE:1262 | Apoptosis | ||||||
| AOP:242 | Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity | Unclassified | - | Fish | 0.12 | KE:636 | Decreased, survival |
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.29 | KE:1392 | Oxidative Stress |
| KE:1514 | Neurodegeneration | ||||||
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development | |
| AOP:279 | Microtubule interacting drugs lead to peripheral neuropathy | Nervous system disease | - | 0.25 | KE:1583 | Sensory axonal peripheral neuropathy | |
| AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic disease; Chromosomal disease | WPHA/WNT Endorsed | Human, Mice, Rat, Fish | 0.2 | KE:1636 | Increase, Chromosomal aberrations |
| AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.2 | KE:1250 | Decrease, Lung function |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.2 | KE:1757 | Reduce, Sperm count | |
| AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | Teleost fish | 0.33 | KE:807 | Decreased, cholesterol |
| KE:2147 | Decreased, Viable Offspring | ||||||
| AOP:362 | Immune mediated hepatitis | Gastrointestinal system disease; Immune system disease | - | Homo sapiens, Rat | 0.38 | KE:1820 | Immune mediated hepatitis |
| KE:1633 | Increase in inflammation | ||||||
| KE:1818 | Immune cell activation | ||||||
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.14 | KE:1846 | Thrombosis and Disseminated Intravascular Coagulation |
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.33 | KE:1603 | Chronic kidney disease | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:398 | Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia | Reproductive system disease | Under Development | Mouse, Rat, Human | 0.33 | KE:1881 | Decreased, all-trans retinoic acid (atRA) concentration |
| KE:406 | decreased, Fertility | ||||||
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.17 | KE:1868 | Hyperinflammation | |
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.4 | KE:1250 | Decrease, Lung function | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.75 | KE:1250 | Decrease, Lung function | |
| KE:1923 | Altered gene expression, P53 dependent apoptosis pathway | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited metabolic disorder | - | Human | 0.4 | KE:1953 | Gestational diabetes mellitus |
| KE:1952 | Abnormal, Glucose homeostasis | ||||||
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.33 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.5 | KE:1392 | Oxidative Stress |
| KE:2119 | Insulin resistance, increased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.38 | KE:1868 | Hyperinflammation | |
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.38 | KE:386 | Decrease of neuronal network function |
| KE:389 | Increased, Intracellular Calcium overload | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.38 | KE:1392 | Oxidative Stress |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.27 | KE:188 | Neuroinflammation | |
| KE:55 | Increase, Cell injury/death | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction | ||||||
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.57 | KE:1262 | Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:352 | N/A, Neurodegeneration | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.75 | KE:1392 | Oxidative Stress |
| KE:2150 | Neurological disorder | ||||||
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:519 | Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | Human and other cells in culture, Guinea pig, Rabbit | 0.25 | KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population |
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:341 | Impairment, Learning and memory |
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.57 | KE:1392 | Oxidative Stress |
| KE:2147 | Decreased, Viable Offspring | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1445 | Increase, Lipid peroxidation | ||||||
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.33 | KE:386 | Decrease of neuronal network function | |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.67 | KE:1392 | Oxidative Stress |
| KE:885 | Increase, Cancer | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.56 | KE:389 | Increased, Intracellular Calcium overload |
| KE:1392 | Oxidative Stress | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:188 | Neuroinflammation | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.11 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.29 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| KE:10 | Acetylcholine accumulation in synapses | ||||||
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.1 | KE:25 | Agonism, Androgen receptor |
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.12 | KE:36 | Inhibition, Aromatase |
| AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | Zebra danio, Fathead minnow, Medaka | 0.17 | KE:112 | Antagonism, Estrogen receptor |
| AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.5 | KE:486 | systemic inflammation leading to hepatic steatosis | |
| KE:457 | Activation, SREBF1 | ||||||
| AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive system disease | - | Rattus norvegicus, Homo sapiens | 0.2 | KE:642 | Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol |
| AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus | 0.2 | KE:1614 | Decrease, androgen receptor activation |
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.5 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:25 | Agonism, Androgen receptor | ||||||
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.5 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
| KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | ||||||
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.2 | KE:1617 | Inhibition, 5α-reductase |
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| KE:793 | Increase, Urinary bladder calculi | ||||||
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.36 | KE:800 | Decreased, Aromatase (Cyp19a1) mRNA |
| KE:802 | Increased, HIF-1 alpha transcription | ||||||
| KE:799 | Increased, HIF-1 heterodimer | ||||||
| KE:801 | modulation, Unknown | ||||||
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.18 | KE:819 | Decreased, Glomerular filtration |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.38 | KE:1289 | Perturbation of cholesterol | |
| KE:1286 | Down Regulation, GSS and GSTs gene | ||||||
| KE:1287 | Glutathione synthesis | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.33 | KE:1502 | Histone deacetylase inhibition |
| KE:1262 | Apoptosis | ||||||
| AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.25 | KE:1417 | NFE2/Nrf2 repression | |
| KE:1419 | Reduced, FXR activity | ||||||
| AOP:233 | Mu Opioid Receptor Agonism leading to Analgesia via K Channel Opening | Developmental disorder of mental health | - | 0.2 | KE:1425 | Mu Opioid Receptor Agonism | |
| AOP:234 | Mu Opioid Receptor Agonism leading to Analgesia via Ca Channel Inhibition | Developmental disorder of mental health | - | 0.2 | KE:1425 | Mu Opioid Receptor Agonism | |
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:55 | Increase, Cell injury/death | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.5 | KE:55 | Increase, Cell injury/death | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:55 | Increase, Cell injury/death | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.5 | KE:55 | Increase, Cell injury/death | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal system disease | - | 0.25 | KE:1502 | Histone deacetylase inhibition | |
| AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural tube defect | - | 0.2 | KE:1502 | Histone deacetylase inhibition | |
| AOP:277 | Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response | Immune system disease | WPHA/WNT Endorsed | Homo sapiens, Mus musculus, Rattus norvegicus | 0.5 | KE:1700 | Impaired IL-1R1 signaling in T cell |
| KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.25 | KE:1609 | Inhibition, Cytochrome P450 enzyme (CYP17A1) activity |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| AOP:289 | Inhibition of 5α-reductase leading to impaired fecundity in female fish | Unclassified | Under Development | Fish | 0.17 | KE:1617 | Inhibition, 5α-reductase |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:1656 | Antagonism, Thyroid Receptor |
| AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.6 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| KE:1617 | Inhibition, 5α-reductase | ||||||
| AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.75 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:312 | Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement | Unclassified | - | 0.33 | KE:12 | Acetylcholinesterase (AchE) Inhibition | |
| KE:10 | Acetylcholine accumulation in synapses | ||||||
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:318 | Glucocorticoid Receptor activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.2 | KE:122 | Activation, Glucocorticoid Receptor | |
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.5 | KE:55 | Increase, Cell injury/death |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.75 | KE:55 | Increase, Cell injury/death |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1445 | Increase, Lipid peroxidation | ||||||
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.5 | KE:55 | Increase, Cell injury/death |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.4 | KE:1115 | Increase, Reactive oxygen species |
| KE:1445 | Increase, Lipid peroxidation | ||||||
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1445 | Increase, Lipid peroxidation | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:334 | Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration | Unclassified | - | Teleost fish | 0.17 | KE:122 | Activation, Glucocorticoid Receptor |
| AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.75 | KE:286 | Altered, Transcription of genes by the androgen receptor | |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.2 | KE:36 | Inhibition, Aromatase |
| AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine system disease; Reproductive system disease; Cancer | - | 0.6 | KE:286 | Altered, Transcription of genes by the androgen receptor | |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:376 | Androgen receptor agonism leading to male-biased sex ratio | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Fathead minnow, Channel catfish, Oreochromis niloticus, Chinook salmon | 0.25 | KE:25 | Agonism, Androgen receptor |
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.6 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| KE:10 | Acetylcholine accumulation in synapses | ||||||
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.11 | KE:1046 | Suppression, Estrogen receptor (ER) activity |
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha | |
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1445 | Increase, Lipid peroxidation | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:1250 | Decrease, Lung function | ||||||
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.36 | KE:1392 | Oxidative Stress | |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.15 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:1656 | Antagonism, Thyroid Receptor |
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.29 | KE:1392 | Oxidative Stress |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.5 | KE:2126 | Estrogen receptor alpha inactivation |
| KE:1633 | Increase in inflammation | ||||||
| KE:2125 | Increased fat mass | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| KE:2119 | Insulin resistance, increased | ||||||
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.44 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:286 | Altered, Transcription of genes by the androgen receptor | ||||||
| KE:25 | Agonism, Androgen receptor | ||||||
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | Zebrafish | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| KE:25 | Agonism, Androgen receptor | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.33 | KE:1392 | Oxidative Stress |
| KE:1417 | NFE2/Nrf2 repression | ||||||
| AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.14 | KE:1417 | NFE2/Nrf2 repression |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.29 | KE:1392 | Oxidative Stress | |
| KE:1417 | NFE2/Nrf2 repression | ||||||
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.12 | KE:1392 | Oxidative Stress |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor | |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.33 | KE:1392 | Oxidative Stress | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.23 | KE:1493 | Increased Pro-inflammatory mediators | |
| KE:1392 | Oxidative Stress | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:36 | Inhibition, Aromatase | |
| AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | Human and other cells in culture, Rattus norvegicus, Dogs, Sus scrofa, Zebrafish, Insecta sp. BOLD:AAN5199 | 0.2 | KE:12 | Acetylcholinesterase (AchE) Inhibition |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.4 | KE:408 | reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
| KE:406 | decreased, Fertility | ||||||
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 1.0 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1392 | Oxidative Stress | ||||||
| KE:1538 | Decreased protection against oxidative stress | ||||||
| KE:1492 | Tissue resident cell activation | ||||||
| KE:55 | Increase, Cell injury/death | ||||||
| KE:1487 | Binding, Thiol/seleno-proteins involved in protection against oxidative stress | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| KE:188 | Neuroinflammation | ||||||
| KE:386 | Decrease of neuronal network function | ||||||
| KE:1488 | Glutamate dyshomeostasis | ||||||
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.6 | KE:286 | Altered, Transcription of genes by the androgen receptor | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| KE:337 | N/A, Impairment of reproductive capacity | ||||||
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.43 | KE:494 | Glucocorticoid Receptor Agonist, Activation |
| KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.5 | KE:389 | Increased, Intracellular Calcium overload | |
| KE:352 | N/A, Neurodegeneration | ||||||
| KE:55 | Increase, Cell injury/death | ||||||
| KE:12 | Acetylcholinesterase (AchE) Inhibition | ||||||
| KE:10 | Acetylcholine accumulation in synapses | ||||||
| AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine system disease; Reproductive system disease; Reproductive system disease | Under Development | Mammals | 0.67 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| KE:1614 | Decrease, androgen receptor activation | ||||||
| KE:26 | Antagonism, Androgen receptor | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 1.0 | KE:1867 | Bradykinin system, hyperactivated |
| KE:1496 | Increased, secretion of proinflammatory mediators | ||||||
| KE:1866 | Fibrinolysis, decreased | ||||||
| KE:1868 | Hyperinflammation | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory system disease | - | Homo sapiens | 0.5 | KE:1392 | Oxidative Stress |
| KE:1250 | Decrease, Lung function | ||||||
| AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory system disease | - | Human | 0.33 | KE:1392 | Oxidative Stress |
| KE:1250 | Decrease, Lung function | ||||||
| AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory system disease | - | Human | 0.33 | KE:1392 | Oxidative Stress |
| KE:1250 | Decrease, Lung function | ||||||
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.33 | KE:1392 | Oxidative Stress | |
| KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1919 | Increased, Cardiac Dysregulation | ||||||
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.5 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:759 | Increased, Kidney Failure | ||||||
| KE:1633 | Increase in inflammation | ||||||
| KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.24 | KE:1392 | Oxidative Stress | |
| KE:2001 | Cardiac hypertrophy | ||||||
| KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.57 | KE:1392 | Oxidative Stress |
| KE:12 | Acetylcholinesterase (AchE) Inhibition | ||||||
| KE:1583 | Sensory axonal peripheral neuropathy | ||||||
| KE:352 | N/A, Neurodegeneration | ||||||
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.56 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:759 | Increased, Kidney Failure | ||||||
| KE:149 | Increase, Inflammation | ||||||
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 1.0 | KE:1115 | Increase, Reactive oxygen species |
| KE:130 | Depletion, GSH | ||||||
| KE:1445 | Increase, Lipid peroxidation | ||||||
| KE:2131 | Conjugation, GSH | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.62 | KE:2126 | Estrogen receptor alpha inactivation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1392 | Oxidative Stress | ||||||
| KE:2145 | Metabolic syndrome | ||||||
| KE:2119 | Insulin resistance, increased | ||||||
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.8 | KE:1392 | Oxidative Stress |
| KE:885 | Increase, Cancer | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.4 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.31 | KE:2216 | Binding of antagonist to thyroid hormone receptor | |
| KE:1656 | Antagonism, Thyroid Receptor | ||||||
| KE:2115 | Altered, cholesterol metabolism | ||||||
| KE:341 | Impairment, Learning and memory |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.